67.3% of Trials Disrupted by COVID-19 are Due to Enrollment Suspension

Article

Applied Clinical Trials

GlobalData has found that the majority of disrupted clinical trials 67.3%, were due to the suspension of enrollment. The delayed initiation of planned trials follows at 18.4%, then, 14.4% of trials are currently being impacted due to slow enrollment. 

For more information and findings, click here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.